Published on 12 Jan 2024 on Simply Wall St. via Yahoo Finance
Prelude Therapeutics Incorporated (NASDAQ:PRLD) is definitely on the radar of hedge funds investors...
Key Insights
Given the large stake in the stock by institutions, Prelude Therapeutics' stock price might be vulnerable to their trading decisionsThe top 2 shareholders own 54% of the companyOwnership research, combined with past performance data can help provide a good understanding of opportunities in a stock
Every investor in Prelude Therapeutics Incorporated (NASDAQ:PRLD) should be aware of the most powerful shareholder groups. We can see that hedge funds own the lion's share in the company with 33% ownership. In other words, the group stands to gain the most (or lose the most) from their investment into the company.